Dexmedetomidine

Overview

Dexmedetomidine is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL778).

API suppliers (12)

Suppliers of Dexmedetomidine backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MOEHS IBERICA SLSpain2 active DMF
• GLAND PHARMA LTDIndia2 active DMF
• EDMOND PHARMAItaly1 active DMF
• FERMION OYFinland1 active DMF
• STERLING WISCONSIN LLC1 active DMF
• YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD1 active DMF
• EDMOND PHARMAItaly1 active DMF
• EDMOND PHARMAItaly1 active DMF
• FERMION OYFinland1 active DMF
• STERLING WISCONSIN LLC1 active DMF
• CHEMWERTH INC1 active DMF
• Orion CorporationFinland

Patent & exclusivity (US)

Per the FDA Orange Book (59 approved US products), the latest listed US patent on Dexmedetomidine expires 12 Jan 2043 and exclusivity 19 Nov 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole

Canonical SMILES

CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C

InChIKey

CUHVIMMYOGQXCV-NSHDSACASA-N